Celyad Oncology's share price soared on the Paris Bourse on Tuesday, following the publication of preclinical and clinical data providing proof of concept for its allogeneic CAR-T candidate.

The publication in the International Journal of Molecular Science (IJMS) includes preclinical data on its non-genome-editing allogeneic candidate, CYAD-211.

The publication also presents clinical data from the dose escalation segment of the Phase I clinical trial in patients with relapsed or refractory (r/r) multiple myeloma (MM).

Overall, these data provide proof-of-concept for the safe delivery of engineered CAR-T cells using miRNA-based shRNA technology", says Celyad in a press release.

CYAD-211, the first allogeneic CAR-T candidate using a non-genome-editing approach to achieve allogeneicity, a strategy that Celyad presents as easy to implement, safe, effective and scalable.

Shortly before 12:00 p.m., the share price had soared by almost 110%, after having been booked higher on several occasions, returning to its highest level since November.

Copyright (c) 2025 CercleFinance.com. All rights reserved.